Skip to content

Duchenne drug Givinostat shows success in Phase 3 clinical trial

29 June 2022

On Saturday, 25 June, Italfarmaco Group announced positive data from the completed placebo-controlled Phase 3 trial involving a drug called Givinostat. Givinostat is a drug from a family of molecules called HDAC inhibitors that aims to restore muscle regeneration, increase muscle mass, and reduce inflammation and scar tissue accumulation in boys with Duchenne MD.

The trial (NCT02851797) included 179 ambulant boys who were given either the drug or a placebo. The study shows slower disease progression over 18 months of treatment with Givinostat. In addition, the boys in the study predominantly experienced minor to moderate side effects. The drug effects were measured through physical tests including the stair climb test as the primary outcome measure, as well as several other secondary outcome measures. These included assessments that will be familiar to people with Duchenne muscular dystrophy such as the North Star Ambulatory Assessment (NSAA) and time to rise from the floor. 

We have yet to hear the company’s plans to develop this as a treatment for people living with Duchenne muscular dystrophy. 

For further information, you can read the whole press release here

Join the Muscular Dystrophy UK community

Share your experience and find advice from others with similar conditions.